Oxford Ultrasound Study Uncovers How Brain Resolves Emotional Ambiguity

Oxford Leads Breakthrough in Non-Invasive Brain Stimulation

Researchers at the University of Oxford have made a significant advance in understanding how the human brain handles emotionally uncertain situations, using a pioneering non-invasive technique to directly influence deep brain structures. This study marks the first time scientists have applied transcranial ultrasound stimulation—or TUS—to the human amygdala, providing causal evidence of its role in interpreting ambiguous social cues like neutral facial expressions.

The amygdala, an almond-shaped cluster of nuclei in the temporal lobe, acts as the brain's primary emotional processing center. It rapidly evaluates threats and rewards, but its precise influence on subtle, ambiguous emotions has remained elusive due to challenges in safely modulating this deep structure without surgery. Oxford's team, led by Associate Professor Miriam Klein-Flügge from the Department of Experimental Psychology and the Oxford Centre for Integrative Neuroimaging (OxCIN), bridged this gap with low-intensity focused ultrasound waves that temporarily alter neural activity.

Navigating Emotional Ambiguity in Everyday Life

Emotional ambiguity arises when social signals, such as a poker-faced colleague or a stranger's fleeting glance, lack clear intent—happy, angry, or neutral? In real-world interactions, misinterpreting these can lead to social anxiety or strained relationships. People with mood disorders like depression often exhibit a negative bias, perceiving neutrality as threat, which perpetuates cycles of withdrawal and low mood.

Prior research relied on correlational imaging like fMRI, showing amygdala hyperactivity in anxiety, but lacked causality. Animal lesion studies hinted at its role, yet human ethics limited replication. This Oxford work changes that, demonstrating how the basolateral amygdala (BLA)—the amygdala's main input-output hub—resolves such uncertainty by biasing perceptions toward caution or positivity.

Transcranial Ultrasound Stimulation: A Game-Changer for Deep Brain Access

Transcranial ultrasound stimulation (TUS) uses high-frequency sound waves to focally disrupt or inhibit neurons millimeter-deep in the skull, passing through bone harmlessly at low intensities. Unlike TMS, limited to cortex, or DBS requiring implants, TUS offers reversible, precise neuromodulation. Oxford pioneered human TUS protocols over years, establishing safety for amygdala targeting.

In the experiment, 29 healthy volunteers underwent offline TUS—brief pulses to bilateral BLA, mid-insula (control), or sham—in counterbalanced sessions. Post-stimulation, they completed an emotional learning task: viewing morphed faces (angry to happy continuum) and deciding to approach or avoid based on prior feedback. High-resolution 7T MRI measured resting-state connectivity and metabolites like GABA, confirming target engagement.

Behavioral Shifts: From Caution to Approach

BLA-TUS profoundly altered decisions. Participants showed increased approach tendencies toward neutral faces, treating them more like happy ones—a shift from typical negativity bias. Reaction times slowed specifically for neutral and happy faces, suggesting blurred distinctions in positive-ambiguous emotions. Volume-dependent effects scaled with stimulated tissue, underscoring precision.

Insula-TUS yielded opposite patterns—increased avoidance of ambiguous faces—while sham had none. Feedback learning remained intact, isolating emotion processing. These specific, reversible changes prove TUS's utility.

Neurobiological Confirmation at 7T Resolution

Post-TUS scans revealed reduced BLA functional connectivity—its 'fingerprint' with prefrontal, visual, and salience networks—indicating silenced communication. Metabolite spectra showed lowered excitation/inhibition (E/I) balance via GABA shifts, consistent with inhibition. No mood changes occurred, ensuring subtlety.

This multi-modal validation—behavior, connectivity, neurochemistry—sets a gold standard for TUS studies. The full study in Neuron details these metrics.

Photo by Brad on Unsplash

Specificity Ensures Causal Insights

Controls were rigorous: BLA effects didn't generalize to learning or other emotions; insula stimulation diverged predictably (threat bias). No carryover across sessions, thanks to offline design. This specificity implicates BLA uniquely in ambiguity resolution, not broad emotion or motivation.

• BLA-TUS: Positive bias in ambiguity, RT slowing for positives.
• Insula-TUS: Negative bias reinforcement.
• Sham: Baseline performance.

Bridging to Mood Disorders: A New Therapeutic Avenue?

Depression and anxiety feature amygdala hyperactivity, fostering negative ambiguity interpretations that sustain rumination. Across Europe, 84 million suffer anxiety (17% prevalence), 25 million depression (EF). TUS could normalize this non-invasively, unlike drugs' broad effects or surgery's risks.

Professor Klein-Flügge notes: "The amygdala is a core region changed in mood disorders... an obvious next step is to see if abnormal amygdala metabolism can be restored in patients." Early TUS trials for PTSD show promise; Oxford eyes clinical translation. Oxford's press release highlights this potential.

Oxford's Legacy in Neuromodulation Innovation

Oxford's OhRC and OxCIN have led TUS since early 2020s, from macaque safety to human pilots. Collaborators like Robin Cleveland engineered skull-passing parameters. This builds on ERC/Wellcome-funded work, positioning Oxford as Europe's TUS hub alongside Plymouth's CENTUS and Radboud's efforts.

Such interdisciplinary feats—psychology, engineering, neuroimaging—attract top talent, fostering Europe's neuroscience excellence.

European Landscape: Expanding TUS Frontiers

Beyond Oxford, UK Plymouth advances TUS biomechanics; Netherlands' Radboud targets cognition; Germany's MPI CBS explores. EU Horizon funds collaborative TUS for Parkinson's, addiction. Yet Oxford's amygdala first sets benchmark, spurring pan-European trials.

Future Horizons: From Lab to Clinic

Next: Patient studies restoring amygdala balance in depression. Portable TUS devices loom, enabling home therapy. Ethical frameworks evolve with EU regs. Long-term, integrates with AI diagnostics for personalized neuromodulation.

Careers boom: PhDs in TUS engineering, postdocs in clinical translation at Oxford, ERC grants abundant.

Photo by Lewis Keegan on Unsplash

Cultivating Talent in Europe's Neuroscience Hubs

Oxford's success underscores Europe's higher ed strength. Programs like Wellcome Trust PhDs train next-gen. For aspiring researchers, Europe's unis offer vibrant paths—from MSc neuroimaging at UCL to fellowships at Max Planck.